The CGHS rate revision could lift hospital chains' revenues and margins, say analysts. Here are the listed stocks set to benefit most from the policy update
Medicines, including some life saving drugs, and medical devices are set to become cheaper from Monday with the new GST rates kicking in, making healthcare more affordable and accessible for every citizen, according to industry players. With the landmark GST reforms announced by Prime Minister Narendra Modi come into effect from September 22, it will make healthcare more affordable and accessible for every citizen, Indian Pharmaceutical Alliance Secretary General Sudarshan Jain said. "Most medicines, earlier taxed at 12 per cent, will now attract just 5 per cent GST. In addition, 36 critical life-saving drugs for cancer, genetic and rare diseases, and cardiovascular conditions have been fully exempted," he added. The GST Council has also rationalised tax slabs on health and life insurance premiums, glucometers, and corrective spectacles, Jain said. "These measures mark a transformative shift in India's healthcare landscape, delivering direct savings to patients, easing the burden o
Tern Group secured $24 mn in Series A funding led by Notion Capital to expand nurse training, strengthen its AI talent platform, and scale healthcare placements globally
The company will widen its Bengaluru capability centre, targeting headcount growth to 400 from 250 by end-2025
Nathealth urges the government to cap GST input slabs for healthcare at 5% and allow input credits, citing rising embedded taxes that increase costs for providers and patients
AHH aims for 20 nephrology and urology hospitals under AINU by FY30, plans GI expansion, and leaves IPO timing to investor decision despite readiness within 18 months
The government on Wednesday said as many as 4,019 Mobile Veterinary Units (MVUs) have been made operational in 29 states and union territories since their launch in 2021-22. "Presently, there is no plan at present to expand the MVU programme beyond the existing states and union territories," Minister of State for Fisheries, Animal Husbandry and Dairying S P Singh Baghel, in his written reply to the Rajya Sabha. The mobile veterinary units are operational in 29 states and union territories. "So far, 91.56 lakh farmers have benefited and 1.90 crore animals have been treated with the help of MVUs," he said. The scheme, which was launched during 2021-22, became fully functional by FY 2023-24 and hence no mid-term review could be done for MVUs, he added.
Yaccarino, one of Elon Musk's top deputies, stepped down from her role at the social media site in July
Medical inflation forces Niva Bupa to revise pricing; expects 25% growth in FY26
With a federated architecture, no health records will be stored in a central repository, reducing the risk of a single hacked server leading to leakages
Fund II will invest and back about eight to 10 new companies over the next four years
Angel One and LivWell announce a joint venture to set up a digital-first life insurance firm in India with Rs 4 bn capital, aiming to improve access and affordability
Under the agreement, Fortis will manage operations of six Gleneagles hospitals and one clinic, earning a monthly fee and expanding its bed capacity and national presence
Chennai-based Aarthi Scans plans to add 65 new centres by 2030, with 90% in North India, while exploring fitness diagnostics and targeting a Rs 600 crore turnover
Tricog Health and Omron aim to screen 100 million patients for cardiac health by 2030 with KeeboHealth, an AI-powered connected health platform integrating remote monitoring & real-time data analytics
Shares of Kerala Ayurveda zoomed 20% to ₹511.70 on the BSE in Monday's intra-day trade with 2.87 million shares representing 23.9% of total equity changing hands till 1:11 PM.
Inventurus Knowledge Solutions shares fell after a 1.5% stake changed hands in a block deal; buyer and seller unknown
India's healthcare sector is on the cusp of significant transformation, driven by increased public and private investments, policy initiatives, and demographic shifts, believe analysts.
Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster injectable obesity drugs from Denmark's Novo Nordisk and U.S.-based Eli Lilly
Indegene shares fell after 12 per cent equity, changed hands in two block trades